한글목차

전 세계 약물 스크리닝 시장 규모는 2025년 103억 6,000만 달러로 평가되었고, 2030년까지 212억 9,000만 달러에 이를 것으로 예상되며, CAGR은 15.5%를 나타낼 것으로 전망됩니다.

이 시장의 성장은 운송, 건설, 제조 등 안전이 중시되는 분야에서 정부의 규제 강화와 리스크 기반 검사의 확대에 의해 견인되고 있습니다. 이 성장은 세계 약물 사용 증가를 배경으로합니다. 2023년에는 세계 약 3억 1,600만 명이 약물을 사용하고 있으며, 그 증가율은 인구 증가를 상회하고 있습니다. 이로 인해 직장과 도로에서 장애 위험이 높아지고 있습니다. 약물 관련 기능장애는 연간 약 130만명의 사망자를 내고 있는 도로교통사고(RTI)의 중대한 요인이며, 그 93%가 저소득 및 중산층 국가에서 발생하고 있습니다. 이 상황은 세계의 거리 검사 및 사고 후 약물 스크리닝 프로그램의 필요성을 더욱 강화하고 있습니다.

미국에서는 2023년 직장에서 사고 후 약물 양성률이 10.4%에 이르렀고, 마리화나의 양성률은 25년 만에 높은 수준인 7.5%로 상승했습니다. 이는 성숙 시장에서 유사한 위험 패턴을 나타내며, 무작위 및 사고 후 검사의 도입이 가속되고 있음을 보여줍니다. 결과적으로 고용주 및 규제 당국은 신속하고 법적으로 정당한 스크리닝 및 확인 검사 솔루션을 선호하는 반면, 병원에서 중요한 임상 판단을 지원하기 위해 높은 처리량 LC-MS에 의한 확정 독성 검사에 대한 의존도가 높아지고 있습니다. 동시에, 구강액, 타액, 모발검사의 보급은 변조 위험이 낮고 최근 약물 사용을 보다 정확하게 검출할 수 있기 때문에 검사 프로토콜이 재구성되고 있습니다. 이로 인해 장애율이 증가하고 엄격한 인증 기준을 충족하기 위해 조직은 기존의 약물 스크리닝 기술을 업그레이드해야 합니다.

제공 제품별로 실험실 검사 서비스와 현장 검사 서비스를 포함한 서비스 분야는 예측 기간 동안 약물 스크리닝 시장을 견인할 것으로 예측됩니다. 조직이 종합적이고 관리되는 검사 서비스를 계속 채택하고 있기 때문입니다. 검사실 검사 서비스는 대량의 검사, 확정 검사, 규제 요건에의 대응을 지원해, 현장 검사 서비스는 필요한 현장에서의 신속한 검사를 가능하게 합니다. 컴플라이언스 주도형, 랜덤, 멀티패널 검사 프로그램 증가 경향, 구강액 및 모발 등의 대체 시료 유형의 이용 확대가 전문 서비스 제공업체에 대한 수요를 견인하고 있습니다. 이는 운영 동향에서도 분명하며, 2023년 퀘스트 다이아그노스틱스 약물 스크리닝 지수에 따르면 직원의 검사 부정 사례가 급증하고 있으며 전문적인 관리 및 확인 검사 서비스의 필요성과 복잡성이 높아지고 있습니다. 또한 2025년 직장 동향에서 확장성, 규제 준수 및 통합 보고서는 조직이 약물 스크리닝를 자체 관리가 아닌 외부 위탁하는 주요 요인이 되었습니다. 검사량과 비용이 증가함에 따라 조직은 확장성, 컴플라이언스 및 서비스 지향을 갖춘 약물 스크리닝 솔루션을 적극적으로 채택하여 서비스 시장의 견고한 성장을 지원합니다. 2022년 12월 오메가 연구소는 캐나다 온타리오 주 최첨단 연구소에서 소변 약물 남용 검사 서비스를 시작했습니다. 이 연구소에서는 2023년 1월 3일부터 요중 약물 스크리닝를 제공하여 분자 검사를 보완하는 체제를 갖추고 있습니다.

세계의 약물 스크리닝 시장의 성장은 불법 약물 사용 증가, 노동 안전 위생 우려, 의료 및 법 제도의 변화에 의한 요구의 변화에 지지되고 있습니다. 세계적으로 15세에서 64세의 성인 인구의 9%가 매년 불법 약물을 사용하는 것으로 추정되며 대마초, 오피오이드, 각성제가 가장 확산되고 있습니다. 또한 약물 관련 죽음은 연간 약 60만 명에 이르며 중대한 공중보건 문제임을 부각하고 있습니다. 유럽에서는 성인의 8.4%가 대마초 사용 문제를 안고 있으며, 주로 오피오이드 및 다중 약물 사용으로 인해 약물 관련 사망은 계속 증가하고 있습니다. 이러한 요인에 의해 안전이 특히 중시되는 산업분야에 있어서 세계적으로 직장에서의 사후검사, 랜덤검사, 정기검사의 약물 스크리닝이 확대되고 있습니다. 구강액이나 모발 등의 비침습적 검체 유형의 이용 증가, 도로변 검사나 법 집행 기관에 의한 약물 스크리닝의 확대에 의해 최근의 약물 사용의 검출 정밀도가 향상되어, 검체의 변조 방지를 도모하고 있습니다.

약물 사용 증가 추세와 외부 위탁 검사의 구조적 필요성은 아시아태평양 시장을 견인하고 있습니다. 호주에서는 2022년-2023년도 전국 약물 대책 세대 조사에 의하면 180만명이 매일 흡연, 250만명이 지난 12개월간 대마초 사용, 100만명이 코카인, 660만명이 위험한 음주 습관에 있다고 추계되고 있으며, 의료 및 직장 환경에서의 임상 독물학 및 약물 모니터링 서비스의 지속적인 수요를 반영하고 있습니다. 또한, 코카인과 전자담배를 포함한 불법 약물 사용이 젊은 성인층과 여성 사이에서 증가하고 있으며, 기존의 고위험층을 넘어 검사 대상 인구의 확대로 이어지고 있습니다. 인도에서는 그 수치가 더욱 두드러집니다. 전국 조사 데이터에 따르면 인구의 14.6%(약 1억 6,000만명)가 현재 알코올을 섭취하고 있으며, 3,100만명이 대마를 사용, 2,000만명 이상이 오피오이드를 사용하고 있으며, 약 600만명이 치료 서비스를 필요로 하고 있습니다. 게다가 1,180만명이 진정제를 남용하고, 추정 85만명이 약물을 주사하고 있으며, 병원, 재활시설, 공중위생의 현장에서 검사실 기반의 독물검사가 계속 필요합니다.

Labcorp(미국), Quest Diagnostics Incorporated(미국), Abbott(미국)는 약물 스크리닝 시장에서 주요 기업의 일부입니다.

• 이 연구는 약물 스크리닝 시장에서 이러한 주요 기업에 대해 기업 프로파일, 최근 동향, 주요 시장 전략 등 상세한 경쟁 분석을 수행합니다.

조사 대상

본 보고서에서는 제공 제품별, 검체 유형별, 약물 유형별, 최종 사용자별, 지역별로 분류하고 있습니다. 이 보고서의 조사 범위는 약물 스크리닝 시장의 성장에 영향을 미치는 주요 요인(추진 요인, 억제요인, 과제, 기회 등)에 대한 자세한 정보를 다룹니다. 주요 업계 진출기업의 상세한 분석을 실시해, 각사의 사업 개요, 솔루션, 서비스, 주요 전략, 계약, 제휴 및 합의, 신제품 및 서비스 발표, 합병 및 인수, 약물 스크리닝 시장에 관련하는 최근의 동향에 관한 지견을 제공하겠습니다. 이 보고서는 약물 스크리닝 시장 생태계의 신흥 신생 기업 경쟁 분석을 다루고 있습니다.

이 보고서 구매의 이점

이 보고서는 시장 리더 및 신규 진출기업에게 약물 스크리닝 시장 및 하위 부문의 수익 수치에 대한 가장 정확한 추정치를 제공합니다. 이를 통해 이해관계자는 경쟁 구도를 이해하고 비즈니스 포지셔닝 최적화 및 적절한 시장 진출 전략을 수립하기 위한 인사이트력을 얻을 수 있습니다. 또한 시장 동향을 파악하고 주요 시장 성장 촉진요인, 억제요인, 과제 및 기회에 대한 정보를 제공합니다.

이 보고서는 다음 포인트에 대한 인사이트력을 제공합니다.

• 주요 촉진요인 분석(불법 약물, 알코올 소비 증가, 약물 및 알코올 검사를 의무화하는 엄격한 법규제 시행, 약물 스크리닝 제품 및 서비스에 대한 규제 승인 건수 증가) 제약 요인(이슬람 국가에서의 알코올 소비의 금지, 직장에서의 약물 스크리닝의 금지) 기회(구강내 액체 검사의 보급, 직장에서 지문 기반 의약품 검사 도입, 신흥 경제국에서의 높은 성장 기회)(구강액 검사의 보급, 직장에서의 지문 기반의 약물 스크리닝의 도입, 신흥 경제국에서의 높은 성장 기회) 과제(호기 검사 장치의 정밀도와 특이성에 관한 우려, 약물 스크리닝에 있어서의 거짓 양성 및 음성 결과)가 약물 스크리닝 시장의 성장에 영향을 주고 있습니다.
• 제품개발 및 혁신 : 약물 스크리닝 시장에서의 향후 기술 동향, 연구 개발 활동, 신제품 및 서비스 투입에 관한 상세한 분석
• 시장 개발 : 수익성이 높은 시장에 대한 종합적인 정보. 이 보고서는 다양한 지역의 약물 스크리닝 시장을 분석합니다.
• 시장 다양화 : 약물 스크리닝 시장의 신제품 및 서비스, 미개척 지역, 최근 동향, 투자에 대한 종합적인 정보
• 경쟁 평가 : LabCorp(미국), Quest Diagnostics Incorporated(미국), 애봇(미국), OraSure Technologies Inc.(미국), Alfa Scientific Designs Inc.(미국), Thermo Fisher Scientific Inc.(미국), Dragerwerk AG &Co. KGaA(독일) 등 주요 기업별, 약물 스크리닝 시장에서 시장 점유율, 성장 전략, 서비스 제공에 관한 상세한 평가

목차

제1장 서론

제2장 주요 요약

제3장 중요 인사이트

제4장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
  • 과제
• 미충족 요구와 미개척 시장
• 상호접속된 시장과 분야간 기회
• Tier 1/2/3 참가 기업의 전략적 움직임

제5장 업계 동향

• Porter's Five Forces 분석
• 거시경제지표
• 밸류체인 분석
• 생태계 분석
• 가격 분석
• 2026년-2027년의 주된 회의와 이벤트
• 고객의 비즈니스에 영향을 미치는 동향/혁신
• 투자 및 자금조달 시나리오
• 사례 연구 분석
• 2025년 미국 관세가 약물 스크리닝 시장에 미치는 영향

제6장 기술, 특허, 디지털 AI 도입에 의한 전략적 파괴

• 주요 신기술
• 보완적 기술
• 인접 기술
• 기술/제품 로드맵
• 특허 분석
• 미래의 응용
• AI/생성형 AI가 약물 스크리닝 시장에 미치는 영향

제7장 고객정세와 구매행동

• 의사결정 프로세스
• 구매자의 이해관계자와 구매평가기준
• 채택 장벽과 내부 과제
• 다양한 최종 이용 산업으로부터의 미충족 요구
• 시장 수익성

제8장 규제 상황

• 지역 규제 및 규정 준수
  • 규제기관, 정부기관, 기타 조직
  • 규제 프레임워크
  • 업계 표준

제9장 약물 스크리닝 시장(제공 제품별)

• 서비스
• 제품

제10장 약물 스크리닝 시장(검체 유형별)

• 소변 샘플
• 호흡 샘플
• 구강액 샘플
• 모발 샘플
• 기타 샘플

제11장 약물 스크리닝 시장(약물 유형별)

• 대마초
• 알코올
• 코카인
• 오피오이드
• 암페타민과 메스암페타민
• 기타

제12장 약물 스크리닝 시장(최종사용자별)

• 약물 스크리닝 연구소
• 직장
• 형사 사법 제도 및 법 집행 기관
• 병원
• 약물 치료 센터
• 개인 사용자
• 통증 관리 센터
• 학교 및 대학
• 기타

제13장 약물 스크리닝 시장(지역별)

• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 남아프리카
  • 기타

제14장 경쟁 구도

• 개요
• 주요 진입기업의 전략/강점
• 수익 분석, 2020년-2024년
• 시장 점유율 분석, 2024년
• 브랜드 비교
• 기업평가와 재무지표
• 기업평가 매트릭스 : 주요 진입기업, 2024년
• 기업평가 매트릭스 : 스타트업/중소기업, 2024년
• 경쟁 시나리오

제15장 기업 프로파일

• 주요 진출기업
  • LABCORP
  • QUEST DIAGNOSTICS INCORPORATED
  • ABBOTT
  • ORASURE TECHNOLOGIES INC.
  • ALFA SCIENTIFIC DESIGNS INC.
  • THERMO FISHER SCIENTIFIC INC.
  • DRAGERWERK AG & CO. KGAA
  • LIFELOC TECHNOLOGIES, INC.
  • MPD INC.
  • OMEGA LABORATORIES, INC.
  • PREMIER BIOTECH, INC.
  • PSYCHEMEDICS CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • SHIMADZU CORPORATION
  • SIEMENS HEALTHINEERS AG
  • BIO-RAD LABORATORIES, INC.
• 기타 기업
  • CAREHEALTH AMERICA CORP.
  • ACCUSOURCEHR, INC.
  • CORDANT HEALTH SOLUTIONS
  • ADVACARE PHARMA
  • ACM GLOBAL LABORATORIES
  • MILLENNIUM HEALTH
  • CLINICAL REFERENCE LABORATORY, INC.
  • INTOXIMETERS
  • INTOXALOCK

제16장 조사 방법

제17장 부록

영문목차

The global drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a CAGR of 15.5%. The drug screening market is being driven by expanding government mandates and risk-based testing across safety-sensitive sectors such as transportation, construction, and manufacturing. This growth is underpinned by rising global substance use. Around 316 million people worldwide used drugs in 2023, a rate increasing faster than population growth, heightening impairment risks in workplaces and on public roads. Drug-related impairment is a critical contributor to road traffic injuries (RTIs), which cause approximately 1.3 million deaths annually, with 93% occurring in low- and middle-income countries, reinforcing the need for roadside and post-incident drug testing programs globally.

In the US, post-accident workplace drug positivity reached 10.4% in 2023, with marijuana positivity rising to a 25-year high of 7.5%, illustrating similar risk patterns in mature markets and accelerating adoption of random and post-incident testing. As a result, employers and regulators are prioritizing fast, legally defensible screening and confirmatory solutions, while hospitals increasingly rely on high-throughput LC-MS definitive toxicology testing to support critical clinical decisions. At the same time, broader acceptance of oral fluid, saliva, and hair testing is reshaping testing protocols by enabling more accurate detection of recent drug use with lower tampering risk, compelling organizations to upgrade conventional drug screening technologies in response to rising impairment rates and stricter accreditation standards.

"By offering, services segment to account for largest market share"

Based on offering, the services segment, which includes laboratory testing services and onsite testing services, is anticipated to fuel the drug screening market over the forecast period, as organizations continue to adopt comprehensive and managed testing services. Laboratory testing services assist in dealing with a large number of tests, confirmatory tests, and regulatory requirements, whereas onsite testing services facilitate rapid testing at the point of need. The rising trend of compliance-driven, random, and multi-panel testing programs, as well as the increasing use of alternative specimen types such as oral fluid and hair, is driving the demand for specialized service providers. This is also evident in the operational trends, which highlight that, according to the 2023 Quest Diagnostics Drug Testing Index, incidents of workforce test cheating jumped sharply, indicating the growing complexity and need for expert management and confirmatory services. In addition, workplace trends in 2025 highlight that scalability, regulatory compliance, and integrated reporting are key drivers for organizations outsourcing drug testing, rather than managing testing programs in-house. As testing volumes and expenses increase, organizations are increasingly adopting scalable, compliant, and service-oriented drug screening solutions, which support robust growth in the services market. In December 2022, Omega Laboratories launched the Urine Drugs of Abuse Testing Services in its state-of-the-art laboratory in Ontario, Canada. The laboratory offered urine drug testing from January 3, 2023, to complement its molecular testing.

"By end user, drug testing laboratories accounted for largest share of drug screening market in 2024."

The global drug screening market is fueled by the growing prevalence of illicit drug use, occupational health and safety concerns, and changing medical and legal needs. Globally, it is estimated that 9% of the adult population between 15 and 64 years of age uses illicit drugs every year, with cannabis, opioids, and stimulants being the most prevalent, while drug-related deaths contribute to approximately 0.6 million deaths annually, emphasizing a substantial public health problem. In Europe, cannabis use is a problem for 8.4 % of adults, and drug-related deaths continue to increase, largely due to opioids and polysubstance use. These factors are fueling increasing post-incident, random, and routine drug screening in the workplace in safety-sensitive industries worldwide. The increasing use of non-invasive specimen types, such as oral fluid and hair, as well as the expansion of roadside and law enforcement drug testing, is improving the detection of recent drug use and preventing sample tampering.

"APAC to witness the highest growth rate during the forecast period"

The increasing prevalence of substance use and the structural need for outsourced laboratory testing are driving the market in Asia Pacific. In Australia, the 2022-2023 National Drug Strategy Household Survey estimates that 1.8 million people smoke daily, 2.5 million people have used cannabis in the past 12 months, 1.0 million people have used cocaine, and 6.6 million people engage in risky alcohol consumption, reflecting the continued demand for clinical toxicology and substance monitoring services in healthcare and occupational settings. Moreover, illicit substance use, including cocaine and e-cigarettes, is rising among young adults and women, expanding the tested population beyond the traditional high-risk group. In India, the numbers are even more substantial. National survey data show that 14.6% of the population (approximately 160 million people) are current alcohol users, 31 million people use cannabis, and over 20 million people use opioids, with nearly 6 million people in need of treatment services. Furthermore, 11.8 million people misuse sedatives, and an estimated 850,000 people inject drugs, representing a continued need for laboratory-based toxicology testing in hospitals, rehabilitation facilities, and public health settings.

The breakdown of primary participants is as given below:

• By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
• By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
• By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%.

Labcorp (US), Quest Diagnostics Incorporated (US), and Abbott (US) are some of the key players in the drug screening market.

• The study includes an in-depth competitive analysis of these key players in the drug screening market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the drug screening market by offering (products & services), sample type (urine samples, breath samples, oral fluid samples, hair samples, other samples), drug type (cannabis, alcohol, cocaine, opioids, amphetamine and methamphetamine, other drugs) end user (drug testing laboratories, workplaces, criminal justice systems and law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, schools and colleges, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the drug screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the drug screening market. Competitive analysis of upcoming startups in the drug screening market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the drug screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing consumption of illicit drugs and alcohol, Enforcement of stringent laws mandating drug and alcohol testing, Increasing number of regulatory approvals for drug screening products and services) restraints (Ban on alcohol consumption in Islamic countries, Prohibition on workplace drug testing) opportunities (Popularity of oral fluid testing, Introduction of fingerprint-based drug testing at workplaces, High growth opportunities in emerging economies) challenges (Accuracy and specificity concerns in breathalyzers, False positive and negative results in drug screening) influencing the growth of the drug screening market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the drug screening market
• Market Development: Comprehensive information about lucrative markets; the report analyses the drug screening market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the drug screening market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), and Dragerwerk AG & Co. KGaA (Germany), among others, in the drug screening market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN DRUG SCREENING MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 DRUG SCREENING MARKET OVERVIEW
• 3.2 DRUG SCREENING MARKET, BY OFFERING & REGION
• 3.3 DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT
• 3.4 DRUG SCREENING MARKET: DEVELOPED VS. EMERGING ECONOMIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing consumption of illicit drugs and alcohol
    • 4.2.1.2 Enforcement of stringent laws mandating drug and alcohol testing
    • 4.2.1.3 Increasing number of regulatory approvals for drug screening products & services
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Ban on alcohol consumption in Islamic countries
    • 4.2.2.2 Prohibition on workplace drug testing
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Popularity of oral fluid testing
    • 4.2.3.2 Introduction of fingerprint-based drug testing in workplaces
    • 4.2.3.3 High growth opportunities in emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Accuracy and specificity concerns in breathalyzers
    • 4.2.4.2 False positive and negative results in drug screening
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF SUBSTITUTES
  • 5.1.4 THREAT OF NEW ENTRANTS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY TYPE (2024)
  • 5.5.2 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION (2024)
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 CASE STUDY ANALYSIS
• 5.10 IMPACT OF 2025 US TARIFFS ON DRUG SCREENING MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRY/REGION
    • 5.10.4.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Drug testing laboratories
    • 5.10.5.2 Workplaces
    • 5.10.5.3 Criminal justice systems & law enforcement agencies
    • 5.10.5.4 Hospitals
    • 5.10.5.5 Drug treatment centers
    • 5.10.5.6 Individual users
    • 5.10.5.7 Pain management centers
    • 5.10.5.8 Schools & colleges
    • 5.10.5.9 Other end users

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 LC-MS/MS & GC-MS-BASED CONFIRMATORY TESTING TECHNOLOGIES
  • 6.1.2 AI-DRIVEN RESULT INTERPRETATION & QUALITY ASSURANCE TECHNOLOGIES
  • 6.1.3 LABORATORY AUTOMATION & ROBOTICS TECHNOLOGIES
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 MOBILE HEALTH (MHEALTH) & REMOTE COLLECTION TECHNOLOGIES
  • 6.2.2 ANALYTICS & POPULATION-LEVEL DRUG USE SURVEILLANCE TOOLS
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 FORENSIC CASE MANAGEMENT SYSTEMS
  • 6.3.2 WORKFORCE BACKGROUND SCREENING/VERIFICATION SYSTEMS
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 PATENT PUBLICATION TRENDS FOR DRUG SCREENING MARKET
  • 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-ENABLED INTELLIGENT SCREENING AND RESULT INTERPRETATION
  • 6.6.2 CONTINUOUS AND PREDICTIVE DRUG MONITORING APPLICATIONS
  • 6.6.3 DECENTRALIZED, AT-HOME, AND POINT-OF-CARE SCREENING EXPANSION
  • 6.6.4 INTEGRATED COMPLIANCE, FORENSIC, AND PUBLIC HEALTH INTELLIGENCE PLATFORMS
  • 6.6.5 PERSONALIZED AND THERAPEUTIC DRUG SCREENING APPLICATIONS
• 6.7 IMPACT OF AI/GEN AI ON DRUG SCREENING MARKET
  • 6.7.1 INTRODUCTION
  • 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DRUG SCREENING MARKET
  • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
    • 6.7.3.1 AI-driven transformation of preclinical toxicology screening at PathAI
  • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
    • 6.7.4.1 Laboratory & toxicology operations
    • 6.7.4.2 Laboratory information systems (LIS) & compliance infrastructure
    • 6.7.4.3 Clinical care, workplace safety, and monitoring programs
  • 6.7.5 USER READINESS AND IMPACT ASSESSMENT
    • 6.7.5.1 User readiness
      • 6.7.5.1.1 User A: Clinical, reference, and toxicology laboratories
      • 6.7.5.1.2 User B: Healthcare providers, employers, and forensic agencies
    • 6.7.5.2 Impact assessment
      • 6.7.5.2.1 User A: Clinical, reference, and toxicology laboratories
        • 6.7.5.2.1.1 Implementation
        • 6.7.5.2.1.2 Impact
      • 6.7.5.2.2 User B: Healthcare providers, employers, and forensic agencies
        • 6.7.5.2.2.1 Implementation
        • 6.7.5.2.2.2 Impact

7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 7.1 INTRODUCTION
• 7.2 DECISION-MAKING PROCESS
• 7.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 7.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 7.3.2 BUYING CRITERIA
• 7.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 7.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 7.5.1 UNMET NEEDS
  • 7.5.2 END-USER EXPECTATIONS
• 7.6 MARKET PROFITABILITY

8 REGULATORY LANDSCAPE

• 8.1 REGIONAL REGULATIONS & COMPLIANCE
  • 8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 8.1.2 REGULATORY FRAMEWORK
    • 8.1.2.1 North America
    • 8.1.2.2 Europe
    • 8.1.2.3 Asia Pacific
    • 8.1.2.4 Latin America
    • 8.1.2.5 Middle East & Africa
  • 8.1.3 INDUSTRY STANDARDS

9 DRUG SCREENING MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 SERVICES
  • 9.2.1 WORKFORCE DECENTRALIZATION, PANEL COMPLEXITY, AND LITIGATION-READY TESTING TO DRIVE SUSTAINED MARKET GROWTH
  • 9.2.2 LABORATORY TESTING SERVICES
    • 9.2.2.1 Ability to ensure analytical rigor and compliance with regulatory standards to drive demand
  • 9.2.3 ON-SITE TESTING SERVICES
    • 9.2.3.1 Ability to deliver rapid, point-of-care screening solutions to drive market growth
• 9.3 PRODUCTS
  • 9.3.1 ANALYTICAL INSTRUMENTS MARKET, BY TYPE
    • 9.3.1.1 Breathalyzers
      • 9.3.1.1.1 Fuel-cell breathalyzers
        • 9.3.1.1.1.1 Extremely high accuracy, sensitivity, and reliability to drive demand for fuel-cell breathalyzers
      • 9.3.1.1.2 Semiconductor breathalyzers
        • 9.3.1.1.2.1 Lower prices of semiconductor breathalyzers to drive adoption
      • 9.3.1.1.3 Other breathalyzers
    • 9.3.1.2 Immunoassay analyzers
      • 9.3.1.2.1 Growing adoption of high-throughput immunoassay platforms to power modern toxicology
    • 9.3.1.3 Chromatography instruments
      • 9.3.1.3.1 Advantages such as precise, high-sensitivity analysis in forensic, clinical, and regulatory laboratories to fuel growth
  • 9.3.2 ANALYTICAL INSTRUMENTS MARKET, BY MODALITY
    • 9.3.2.1 Handheld breathalyzers
      • 9.3.2.1.1 Critical role in delivering fast, accurate, and portable alcohol screening to support market growth
    • 9.3.2.2 Benchtop breathalyzers
      • 9.3.2.2.1 Growing use of benchtop breathalyzers for drug detection analysis to drive growth
  • 9.3.3 RAPID TESTING DEVICES
    • 9.3.3.1 Urine testing devices
      • 9.3.3.1.1 Drug testing cups
        • 9.3.3.1.1.1 Reduced contact with urine sample to drive demand
      • 9.3.3.1.2 Dip cards
        • 9.3.3.1.2.1 Ability to provide qualitative results within minutes to propel market
      • 9.3.3.1.3 Drug testing cassettes
        • 9.3.3.1.3.1 Lower cost alternatives to drug testing cups and dip cards to boost adoption
    • 9.3.3.2 Oral fluid testing devices
      • 9.3.3.2.1 Rapid, non-invasive detection of recent drug use across workplace, clinical, and law enforcement settings to fuel growth
  • 9.3.4 CONSUMABLES
    • 9.3.4.1 Assay kits
      • 9.3.4.1.1 Rapid, cost-effective, and high-throughput screening across drug testing applications to drive market
    • 9.3.4.2 Sample collection devices
      • 9.3.4.2.1 Reliable, tamper-resistant, and versatile drug testing across settings to support growth
    • 9.3.4.3 Calibrators & controls
      • 9.3.4.3.1 Ability to verify accuracy, precision, and reliability of screening and confirmatory test results to drive growth
    • 9.3.4.4 Other consumables

10 DRUG SCREENING MARKET, BY SAMPLE TYPE

• 10.1 INTRODUCTION
• 10.2 URINE SAMPLES
  • 10.2.1 RECENT ADVANCES TO STRENGTHEN ACCURACY AND RELIABILITY IN URINE DRUG TESTING
• 10.3 BREATH SAMPLES
  • 10.3.1 BREATH ALCOHOL TESTS TO REGISTER WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS
• 10.4 ORAL FLUID SAMPLES
  • 10.4.1 NON-INVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION TO SUPPORT USAGE OF ORAL FLUID SAMPLES
• 10.5 HAIR SAMPLES
  • 10.5.1 ABILITY OF HAIR SAMPLES TO PROVIDE INSIGHTS INTO LONG-TERM DRUG USE TO BOOST MARKET
• 10.6 OTHER SAMPLES

11 DRUG SCREENING MARKET, BY DRUG TYPE

• 11.1 INTRODUCTION
• 11.2 CANNABIS
  • 11.2.1 GROWING CANNABIS USE AND REGULATORY COMPLEXITY TO DRIVE SUSTAINED DEMAND FOR DRUG SCREENING SOLUTIONS
• 11.3 ALCOHOL
  • 11.3.1 REGULATORY ENFORCEMENT AND TECHNOLOGY INNOVATION TO STRENGTHEN ALCOHOL SCREENING ADOPTION
• 11.4 COCAINE
  • 11.4.1 SHIFT TOWARD RAPID, DEFENSIBLE DETECTION TO POSITION COCAINE AS PRIORITY DRUG IN MODERN SCREENING PANELS
• 11.5 OPIOIDS
  • 11.5.1 EXPANDED OPIOID PANELS AND ADVANCED CONFIRMATORY TECHNOLOGIES TO REINFORCE OPIOID SCREENING AS HIGH PRIORITY
• 11.6 AMPHETAMINES & METHAMPHETAMINES
  • 11.6.1 ADVANCED ANALYTICS AND DIFFERENTIATION TESTING TO REDEFINE AMPHETAMINE & METHAMPHETAMINE DETECTION
• 11.7 OTHER DRUGS

12 DRUG SCREENING MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 DRUG TESTING LABORATORIES
  • 12.2.1 ADVANCED ANALYTICS, AUTOMATION, AND EXPANDING FORENSIC AND CLINICAL DEMAND TO DRIVE MARKET GROWTH
• 12.3 WORKPLACES
  • 12.3.1 RISING NUMBER OF DRUG ABUSE CASES TO INCREASE WORKPLACE TESTING
• 12.4 CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES
  • 12.4.1 HIGH SUBSTANCE-USE PREVALENCE AND DUI RISKS TO DRIVE MANDATORY DRUG & ALCOHOL TESTING
• 12.5 HOSPITALS
  • 12.5.1 RISING EMERGENCY ADMISSIONS, OPIOID OVERDOSES, AND PATIENT SAFETY MANDATES TO DRIVE STRONG DEMAND
• 12.6 DRUG TREATMENT CENTERS
  • 12.6.1 RISING ADOPTION OF MEDICATION-ASSISTED TREATMENT, RELAPSE MONITORING, AND FENTANYL DETECTION TO DRIVE DEMAND
• 12.7 INDIVIDUAL USERS
  • 12.7.1 GROWING SELF-MONITORING, HOME TESTING, AND RECOVERY ACCOUNTABILITY TO EXPANDING INDIVIDUAL USE OF SCREENING
• 12.8 PAIN MANAGEMENT CENTERS
  • 12.8.1 OPIOID PRESCRIBING OVERSIGHT AND PATIENT SAFETY MANDATES TO DRIVE INCREASED DRUG SCREENING
• 12.9 SCHOOLS & COLLEGES
  • 12.9.1 MODERN TESTING AND AWARENESS PROGRAMS TO STRENGTHEN DRUG ABUSE PREVENTION IN SCHOOLS & COLLEGES
• 12.10 OTHER END USERS

13 DRUG SCREENING MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Regulatory enforcement and substance use prevalence drive drug screening market in US
  • 13.2.3 CANADA
    • 13.2.3.1 Public health surveillance, consumption trends, and enforcement & technological advancements to drive market
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Strengthening drug screening adoption through public health policy and technological modernization to support market growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Regulatory enforcement, transport safety, and forensic modernization to shape drug screening market
  • 13.3.4 UK
    • 13.3.4.1 Community-embedded testing, criminal justice demand, and real-time drug surveillance to shape UK drug screening market
  • 13.3.5 ITALY
    • 13.3.5.1 Strengthening drug screening market through roadside enforcement and analytical innovation & institutional capacity
  • 13.3.6 SPAIN
    • 13.3.6.1 Expanding drug screening adoption through road safety programs to drive market growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Synthetic drug control and pharmaceutical innovation to drive drug screening market growth
  • 13.4.3 JAPAN
    • 13.4.3.1 Japan's aging population and advanced digital infrastructure to drive rapid adoption
  • 13.4.4 INDIA
    • 13.4.4.1 Alcohol dominance, opioid misuse, and India's role as global pharmaceutical hub to drive drug screening market growth
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 Harm-reduction policy, workplace safety regulation, and roadside testing to drive drug screening market
  • 13.4.6 SOUTH KOREA
    • 13.4.6.1 Zero-tolerance drug policy, mandatory military service, and forensic-grade testing to shape drug screening market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Brazil's drug screening market to expand amid road safety mandates, substance-use burden, and regulatory enforcement
  • 13.5.3 MEXICO
    • 13.5.3.1 Mexico's drug screening market shaped by methamphetamine prevalence, cross-border labor dynamics, and public safety enforcement
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Saudi Arabia
      • 13.6.2.1.1 Public safety, diagnostic modernization, and evolving consumption patterns to boost market
    • 13.6.2.2 UAE
      • 13.6.2.2.1 Integrated safety enforcement, workplace testing, and diagnostic modernization to expand market in UAE
    • 13.6.2.3 Rest of GCC Countries
  • 13.6.3 SOUTH AFRICA
    • 13.6.3.1 Rising substance use, workplace risk management, and advanced screening capabilities to fuel market growth
  • 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET
• 14.3 REVENUE ANALYSIS, 2020-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 BRAND COMPARISON
• 14.6 COMPANY VALUATION & FINANCIAL METRICS
  • 14.6.1 FINANCIAL METRICS
  • 14.6.2 COMPANY VALUATION
• 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.7.1 STARS
  • 14.7.2 EMERGING LEADERS
  • 14.7.3 PERVASIVE PLAYERS
  • 14.7.4 PARTICIPANTS
  • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.7.5.1 Company footprint
    • 14.7.5.2 Region footprint
    • 14.7.5.3 Offering footprint
    • 14.7.5.4 Sample type footprint
    • 14.7.5.5 Drug type footprint
    • 14.7.5.6 End-user footprint
• 14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.8.1 PROGRESSIVE COMPANIES
  • 14.8.2 RESPONSIVE COMPANIES
  • 14.8.3 DYNAMIC COMPANIES
  • 14.8.4 STARTING BLOCKS
  • 14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.8.5.1 Detailed list of key startups/SMEs
    • 14.8.5.2 Competitive benchmarking of startups/SMEs
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 14.9.2 DEALS
  • 14.9.3 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 LABCORP
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products & services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 QUEST DIAGNOSTICS INCORPORATED
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products & services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product & service launches
      • 15.1.2.3.2 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 ABBOTT
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products & services offered
    • 15.1.3.3 MnM view
      • 15.1.3.3.1 Key strengths
      • 15.1.3.3.2 Strategic choices
      • 15.1.3.3.3 Weaknesses & competitive threats
  • 15.1.4 ORASURE TECHNOLOGIES INC.
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products & services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 ALFA SCIENTIFIC DESIGNS INC.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products & services offered
    • 15.1.5.3 MnM view
      • 15.1.5.3.1 Key strengths
      • 15.1.5.3.2 Strategic choices
      • 15.1.5.3.3 Weaknesses & competitive threats
  • 15.1.6 THERMO FISHER SCIENTIFIC INC.
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products & services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product developments
      • 15.1.6.3.2 Deals
  • 15.1.7 DRAGERWERK AG & CO. KGAA
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products & services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product launches
  • 15.1.8 LIFELOC TECHNOLOGIES, INC.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products & services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Other developments
  • 15.1.9 MPD INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products & services offered
  • 15.1.10 OMEGA LABORATORIES, INC.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products & services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Service launches
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Other developments
  • 15.1.11 PREMIER BIOTECH, INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products & services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
  • 15.1.12 PSYCHEMEDICS CORPORATION
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products & services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches & enhancements
      • 15.1.12.3.2 Other developments
  • 15.1.13 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products & services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
  • 15.1.14 SHIMADZU CORPORATION
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products & services offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches
      • 15.1.14.3.2 Deals
  • 15.1.15 SIEMENS HEALTHINEERS AG
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products & services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches
      • 15.1.15.3.2 Deals
  • 15.1.16 BIO-RAD LABORATORIES, INC.
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products & services offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Product enhancements
      • 15.1.16.3.2 Deals
• 15.2 OTHER PLAYERS
  • 15.2.1 CAREHEALTH AMERICA CORP.
  • 15.2.2 ACCUSOURCEHR, INC.
  • 15.2.3 CORDANT HEALTH SOLUTIONS
  • 15.2.4 ADVACARE PHARMA
  • 15.2.5 ACM GLOBAL LABORATORIES
  • 15.2.6 MILLENNIUM HEALTH
  • 15.2.7 CLINICAL REFERENCE LABORATORY, INC.
  • 15.2.8 INTOXIMETERS
  • 15.2.9 INTOXALOCK

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH APPROACH
  • 16.1.1 SECONDARY RESEARCH
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY RESEARCH
    • 16.1.2.1 Primary sources
    • 16.1.2.2 Key data from primary sources
    • 16.1.2.3 Breakdown of primaries
    • 16.1.2.4 Insights from primary experts
• 16.2 RESEARCH METHODOLOGY DESIGN
• 16.3 MARKET SIZE ESTIMATION
• 16.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 16.5 MARKET SHARE ESTIMATION
• 16.6 STUDY ASSUMPTIONS
• 16.7 RESEARCH LIMITATIONS
  • 16.7.1 METHODOLOGY-RELATED LIMITATIONS
• 16.8 RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS